ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulins

Also written as “IgPro10”, “TAK-771” and “Immunoglobulins Intravenous (Human)”.

Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Agammaglobulinemia · Scleroderma, Diffuse · Purpura, Thrombocytopenic, Idiopathic, led by 4 companies.

Drug pageImmunoglobulins: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 7, 201119 company-led studies, 2 open or runningNext primary completion: Dec 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSLits history only111 open or runningphase 4since Jul 7, 2011Sep 12, 2005Dec 20, 2029phase 4 · NCT03684018
Takedaits history only60 open or runningphase 3since Sep 11, 2015Sep 11, 2015none ahead
GC Biopharma10 open or runningphase 3since Feb 19, 2018Feb 19, 2018none ahead
Kedrionits history only11 open or runningphase 3since Dec 16, 2024Dec 16, 2024Dec 20, 2027phase 3 · NCT06752356

Also a collaborator on its studies: Takeda Development Center Americas.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GC Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 19, 2018First study: phase 3 study in Primary Immunodeficiency DiseasesFirst studyNCT03492710

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study GC Biopharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03492710Primary Immunodeficiency Diseases3WithdrawnApr 30, 20190

How it is read

Names in the registry

  • “IgPro10”, 4 entries
  • “TAK-771”, 3 entries
  • “Immunoglobulins Intravenous (Human)”, 3 entries
  • “Immunoglobulin”, 2 entries
  • “Immune globulin (human) 10% solution for intravenous administration”, 1 entry

Codes read as this program: IGPRO10.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.